Mechanism of action
The MMR vaccine contains live attenuated strains of measles virus (typically Edmonston-Enders or Moraten strains), mumps virus (Jeryl Lynn or related strains), and rubella virus (Wistar RA 27/3 strain). After subcutaneous administration, these attenuated viruses replicate in a limited fashion, triggering both humoral and cell-mediated immune responses without causing clinical disease in immunocompetent individuals.
The vaccine induces production of IgG antibodies against viral surface proteins, providing long-lasting immunity. Measles antibodies target hemagglutinin and fusion proteins; mumps antibodies target hemagglutinin-neuraminidase and fusion proteins; rubella antibodies target envelope glycoproteins E1 and E2. Cell-mediated immunity involves CD4+ and CD8+ T-cell responses that provide additional protection and contribute to immunological memory.
Protective antibody levels typically develop within two to three weeks after the first dose. A second dose significantly boosts antibody titers and provides protection to the small percentage of individuals who did not respond adequately to the first dose (primary vaccine failure). Immunity following two doses is durable, with measles and rubella protection lasting decades and mumps protection somewhat shorter.
- MMR is a live attenuated vaccine contraindicated in pregnancy and severe immunodeficiency
- Administer two doses: first at 12-15 months, second at 4-6 years
- Post-exposure measles prophylaxis is effective within 72 hours of exposure
- Egg allergy is NOT a contraindication to MMR vaccine
- MMR does not cause autism—this claim has been definitively refuted
- Delay MMR for 3-11 months after immune globulin or blood products
- Febrile seizures occur in 1:3,000-4,000 doses, higher with MMRV combination
- Thrombocytopenia is a rare adverse effect occurring within 6 weeks post-vaccination
Indications
The primary indication for MMR vaccine is routine immunization against measles, mumps, and rubella. Standard schedules recommend two doses: the first at age twelve to fifteen months and the second at age four to six years, though the second dose may be given as early as four weeks after the first.
Additional indications include:
- Post-exposure prophylaxis for measles when given within 72 hours of exposure in susceptible individuals
- Catch-up vaccination for children, adolescents, and adults without evidence of immunity
- Pre-travel vaccination for international travelers born after 1957 without immunity documentation
- Healthcare workers, students entering college, and other high-risk populations requiring documentation of immunity
- Outbreak control measures in institutional or community settings
Evidence of immunity includes documented receipt of two doses of MMR vaccine, laboratory confirmation of immunity (positive IgG titers), laboratory-confirmed measles/mumps/rubella disease, or birth before 1957 (presumptive immunity, though healthcare workers still require documentation).
MMR vaccine may be administered simultaneously with other vaccines at different injection sites. It is often combined with varicella vaccine as MMRV, though this formulation carries a slightly higher risk of febrile seizures in young children compared to separate MMR and varicella vaccines.
Pharmacokinetics
The MMR vaccine is administered as a 0.5 mL subcutaneous injection, typically in the lateral upper arm or anterolateral thigh. The live attenuated viruses undergo limited replication at the injection site and in regional lymph nodes before disseminating systemically.
Peak viral replication and antibody responses occur at different times for each component. Measles virus replication peaks around seven to twelve days post-vaccination, mumps around ten to fourteen days, and rubella around seven to fourteen days. These phases may coincide with mild constitutional symptoms or rash in some recipients.
After a single dose, approximately 93-95% of recipients develop protective antibodies to measles, 78-90% to mumps, and 97% to rubella. After two doses, seroconversion rates reach 97-99% for measles, 88-95% for mumps, and 99% for rubella. Antibody persistence varies by component, with measles and rubella antibodies typically lasting for decades, while mumps antibody levels may wane over time, contributing to breakthrough infections.
The vaccine virus is not transmitted person-to-person, distinguishing it from wild-type infections. Vaccine virus can be transiently detected in respiratory secretions or urine but does not pose a transmission risk to contacts, including immunocompromised individuals.
Adverse effects
Most adverse effects of MMR vaccine are mild and self-limited. Common reactions reflect the immune response to live viral replication.
Common adverse effects (occurring in 5-15% of recipients):
- Fever (typically 7-12 days post-vaccination)
- Injection site pain, erythema, or swelling
- Transient measles-like or rubella-like rash (5-12 days post-vaccination)
- Lymphadenopathy
Uncommon adverse effects:
- Parotid swelling (mumps component)
- Febrile seizures (approximately 1 in 3,000-4,000 doses, higher with MMRV)
- Transient thrombocytopenia (1 in 30,000 doses, typically within six weeks)
- Transient arthralgias or arthritis (more common in adult women, rubella component, 25% of postpubertal females)
Rare adverse effects:
- Anaphylaxis (approximately 1 in 1,000,000 doses)
- Immune thrombocytopenic purpura (ITP)
- Aseptic meningitis (mumps component, strain-dependent)
- Encephalitis (less than 1 in 1,000,000 doses, rate lower than background encephalitis rate)
Important: Multiple large epidemiological studies have definitively refuted any association between MMR vaccine and autism spectrum disorder. This claim originated from a fraudulent 1998 study that was retracted, and the author was stripped of his medical license. Extensive research involving millions of children has found no causal link.
Thrombocytopenia after MMR is typically mild and self-resolving. The risk of thrombocytopenia from natural measles infection far exceeds the vaccine risk. Individuals with a history of thrombocytopenia after the first MMR dose should have serologic testing; if immune, the second dose is unnecessary.
Contraindications and warnings
Absolute contraindications:
- Severe immunodeficiency (primary immunodeficiency disorders, HIV with CD4 count <200 cells/μL or <15% in children, active malignancy receiving chemotherapy, high-dose systemic corticosteroids >2 mg/kg/day or >20 mg/day prednisone equivalent for ≥14 days)
- Pregnancy (theoretical risk of congenital rubella syndrome; women should avoid pregnancy for 28 days after vaccination)
- History of severe allergic reaction to a vaccine component (neomycin, gelatin) or previous dose
- Family history of congenital or hereditary immunodeficiency in first-degree relatives (unless immune competence is documented)
Precautions and warnings:
- Recent receipt of antibody-containing blood products may interfere with vaccine response; delay vaccination by three to eleven months depending on the product and dose
- Moderate or severe acute illness with or without fever (defer vaccination)
- History of thrombocytopenia or thrombocytopenic purpura (weigh risks and benefits; check serologic immunity)
- Tuberculosis (active untreated TB; MMR may transiently suppress tuberculin skin testing)
Special populations:
HIV infection: MMR vaccination is recommended for HIV-infected individuals without evidence of severe immunosuppression (CD4 ≥200 cells/μL in adolescents/adults or CD4 percentage ≥15% in children). Two doses separated by at least four weeks are recommended.
Household contacts of immunocompromised individuals: MMR vaccine is safe to administer because vaccine virus is not transmitted. Vaccinating household contacts provides indirect protection.
Breastfeeding: Not a contraindication. Breastfeeding does not interfere with immune response, and vaccine virus is not transmitted through breast milk.
Egg allergy: Not a contraindication. Although measles and mumps vaccine components are grown in chick embryo fibroblasts, the egg protein content is negligible and does not require special precautions, even in individuals with severe egg allergy.
Minor illnesses, concurrent antibiotic use, and personal or family history of seizures are not contraindications. The benefit-risk ratio strongly favors vaccination in the vast majority of clinical scenarios.
Drug interactions
Immunosuppressive medications:
Systemic corticosteroids at immunosuppressive doses, chemotherapy, radiation therapy, and other immunosuppressive agents may reduce immune response to MMR vaccine and increase the risk of vaccine virus dissemination. Vaccination should be deferred until immunosuppressive therapy is discontinued for an adequate interval (typically three months for chemotherapy, one month for high-dose corticosteroids).
Topical, inhaled, and low-dose corticosteroids (<2 mg/kg/day or <20 mg/day prednisone equivalent, or <14 days of higher doses) are not contraindications.
Immune globulin and blood products:
Passively acquired antibodies from immune globulin, blood transfusions, or other antibody-containing products can interfere with the replication of vaccine viruses and reduce immunogenicity. The interval between blood product administration and MMR vaccination depends on the type and dose of the product, ranging from three months (for standard immune globulin) to eleven months (for high-dose intravenous immune globulin for conditions like Kawasaki disease).
If MMR is inadvertently administered during this interval, revaccination is recommended after the appropriate waiting period unless serologic testing confirms adequate antibody response.
Tuberculin skin testing and IGRAs:
MMR vaccine may transiently suppress tuberculin reactivity, potentially causing false-negative tuberculin skin test (TST) results. If TST or interferon-gamma release assay (IGRA) is needed, it should be administered on the same day as MMR or delayed for four to six weeks after vaccination, as live vaccines can suppress results of both tests.
Other live vaccines:
MMR can be administered simultaneously with other live vaccines (varicella, rotavirus, intranasal influenza, yellow fever) at different sites. If not given simultaneously, live vaccines should be separated by at least four weeks to prevent interference with immune responses.
Inactivated vaccines, toxoids, and polysaccharide vaccines can be given at any time before or after MMR without interaction concerns.
Clinical pearls
- Measles is one of the most contagious infectious diseases, with a basic reproduction number (R₀) of 12-18. MMR vaccination is the most effective public health intervention to prevent outbreaks.
- A measles titer showing immunity eliminates the need for additional measles vaccination, even in healthcare workers or travelers. Equivocal results should prompt revaccination or repeat testing.
- Post-exposure prophylaxis with MMR within 72 hours of measles exposure can provide protection or attenuate disease in susceptible individuals. Immune globulin is an alternative within six days for those with contraindications to live vaccine.
- The second MMR dose is not a "booster" but rather a dose to capture individuals who did not respond to the first dose (primary vaccine failure). It should not be delayed beyond the recommended schedule.
- Mumps immunity wanes more rapidly than measles or rubella immunity. During outbreaks, a third dose of MMR may be recommended for high-risk populations to boost protection.
- Egg allergy is not a contraindication to MMR. This is a common misconception; the vaccine can be safely administered without special precautions.
- Pregnancy testing before MMR vaccination is not required. Women should be counseled to avoid pregnancy for 28 days after vaccination, but inadvertent vaccination during pregnancy is not an indication for pregnancy termination (no documented cases of congenital rubella syndrome from vaccine virus).
- Healthcare personnel born before 1957 without laboratory evidence of immunity or disease should still receive two doses of MMR due to their high-risk occupational exposure.
- Serologic testing after MMR vaccination is not routinely recommended except in specific high-risk situations (healthcare workers, outbreak settings, immunocompromised individuals).
- Fever and rash after MMR vaccination are not contraindications to the second dose and do not predict similar reactions with subsequent doses.
- The combination MMRV vaccine (MMR plus varicella) is associated with a slightly increased risk of febrile seizures in children aged twelve to twenty-three months compared to separate MMR and varicella vaccines given at the same visit. This risk is approximately one additional febrile seizure per 2,300-2,600 doses.
Practice questions
1. A 14-month-old girl is brought to the pediatrician for a routine health maintenance visit. She received her first MMR vaccine 2 weeks ago and subsequently developed a fever to 39.2°C (102.6°F) and a maculopapular rash that resolved after 3 days. Her mother is concerned about proceeding with future vaccinations. The child has no other medical problems and takes no medications. Which of the following is the most appropriate next step regarding her immunization schedule?
2. A 28-year-old woman presents to the clinic requesting preconception counseling. She plans to become pregnant in the next few months. Her vaccination history is uncertain, and her measles, mumps, and rubella titers return showing negative rubella IgG antibodies but positive measles and mumps antibodies. Which of the following is the most appropriate management?
3. A 6-year-old boy with acute lymphoblastic leukemia completed his chemotherapy 2 months ago and is in remission. His mother asks about updating his immunizations, as he missed several vaccines during treatment. His absolute lymphocyte count is 1,500/μL and he is otherwise well. Which of the following is the most appropriate recommendation regarding MMR vaccination?
Frequently asked questions
How does MMR vaccine work?
MMR vaccine contains live attenuated (weakened) strains of measles, mumps, and rubella viruses. After injection, these attenuated viruses replicate in a limited way, stimulating the immune system to produce antibodies and memory cells without causing disease. This provides long-lasting protection against all three infections through both humoral (antibody) and cell-mediated immunity.
What are the side effects of MMR vaccine?
Common side effects include fever (occurring 7-12 days after vaccination), injection site pain or swelling, and mild rash. Less common effects include transient joint pain (especially in adult women), parotid swelling, and lymph node enlargement. Rare serious adverse effects include febrile seizures (1 in 3,000-4,000 doses), thrombocytopenia (1 in 30,000), and allergic reactions. Most side effects are mild and self-limiting.
Is MMR vaccine safe during pregnancy?
No, MMR vaccine is contraindicated during pregnancy because it contains live attenuated viruses, and there is a theoretical risk of fetal infection with the rubella vaccine component. Women should avoid pregnancy for 28 days after receiving MMR. However, if a woman is inadvertently vaccinated during pregnancy or becomes pregnant shortly after vaccination, this is not an indication for pregnancy termination, as no cases of congenital rubella syndrome from vaccine virus have been documented.
Can you get MMR vaccine if you are allergic to eggs?
Yes, egg allergy is not a contraindication to MMR vaccine. Although measles and mumps vaccine components are grown in chick embryo fibroblasts, the amount of egg protein in the final vaccine is negligible and does not pose a risk even to individuals with severe egg allergy. MMR can be administered without special precautions regardless of egg allergy history. This is an important distinction from influenza vaccines.
MMR vaccine vs MMRV vaccine—what is the difference?
MMR vaccine protects against measles, mumps, and rubella, while MMRV vaccine protects against measles, mumps, rubella, and varicella (chickenpox). MMRV is a combination vaccine that delivers four antigens in one injection. The main difference is that MMRV has a slightly higher risk of febrile seizures in children aged 12-23 months compared to giving separate MMR and varicella vaccines at the same visit (approximately one additional febrile seizure per 2,300-2,600 doses).
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J07BD52
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.